Overview of the ISPE GAMP® Guide: Records & Data Integrity
The importance of ensuring data integrity is reflected in guidance, citations, and public comments of regulators and health agencies. A number of companies have suffered serious regulatory and financial consequences as a result of unacceptable pharmaceutical data integrity practices. The ISPE GAMP® Guide: Records and Data Integrity provides principles and practical guidance on meeting current expectations for the management of GxP-regulated records and data, ensuring that they are complete, consistent, secure, accurate, and available throughout their life cycle. This approach is intended to encourage innovation and technological advancement while avoiding unacceptable risk to product quality, patient safety, and public health.
The ISPE GAMP Guide: Records and Data Integrity is intended as a stand-alone ISPE GAMP Guide aligned with theISPE GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. It has been designed so that it may be used in parallel with guidance provided in ISPE GAMP 5 and other ISPE GAMP Good Practice Guides. It replaces the previous ISPE GAMP Good Practice Guide: A Risk-Based Approach to Compliant Electronic Records and Signatures.
This Guide has been developed by ISPE’s GAMP Community of Practice (CoP), a worldwide community of practitioners and subject matter experts who over25 years have been developing internationally accepted guidance on risk-based approaches to safeguard patient safety, product quality, and data integrity. This Guide has been produced with significant input and review from regulators worldwide, including key specialists from leading regulatory authorities (MHRA and WHO) working in this area.
The ISPE GAMP Guide: Records and Data Integrity is intended to be a complete and comprehensive single point of reference covering the requirements, expectations, and principles of pharmaceutical data integrity. Topics covered include regulatory focus areas, the data governance framework, the data life cycle, culture and human factors, and the application of quality risk management to data integrity. As such, it is of great interest to anyone with a responsibility for ensuring data integrity, including:
Executives and managers
Process and data owners and data stewards
Technical system owners
System developers, maintainers, and users
Quality assurance and quality control
Clinical, manufacturing, and laboratory personnel
Validation and compliance specialists
Suppliers of systems and services
IT and engineering professionals
Readers will gain an invaluable insight into the pressing hot topic of pharmaceutical data integrity, gaining an in-depth understanding of the key requirements and principles, as well as learn about practical approaches and techniques to effectively address data integrity challenges. The ISPE GAMP Guide: Records and Data Integrity will assist regulated companies and their suppliers to achieve the high level of data integrity expected by regulatory authorities worldwide. Please visit http://www.ispe.org/gampguide/records-pharmaceutical-data-integrity to purchase the Guide.
ISPE also offers a new two-day training course using the Guide, A GAMP Approach to Data Integrity, Electronic Records and Signatures, and Operation GxP Computerized Systems (T50) in San Diego, California, US; Copenhagen, Denmark; Tampa, Florida, US; and Manchester, England, UK. This course provides the tools and techniques to implement proper controls for data to ensure the integrity and validity of the information throughout the data life cycle.
As many of you read this, I am sure your social and work life have been turned upside down, flipped around, and now are possibly settling into “the new normal.” I personally cringed when I wrote that—I was so tired of hearing that phrase about three weeks into the pandemic.
Because of the global pandemic, we have experienced unexpected joys, learned new skills, adjusted to long days of video conferencing, and dealt with drops in income and potential job losses. At the same time, we have also experienced an increased sense of urgency, collaboration, and pride because...
How many times have you heard phrases like these over the last several months: unprecedented marketplace disruptions, staggering economic conditions, or maybe insurmountable business challenges? If you’re like me, probably more than you can count.